Insulin Lispro (Genetical Recombination) Injection 100 units/mL (Lyumjev® / ルムジェブ注カート)

JPY ¥3,600

Japanese Antidiabetic Agent (Insulin Lispro (Genetical Recombination) 100 units/mL). Subcutaneous injection for diabetes mellitus requiring insulin therapy. 3mL x 2 cartridges. Mfd. by Eli Lilly Japan K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥3,312
10 - 19 12% JPY ¥3,168
20 + 18% JPY ¥2,952
SKU: LYM-100-INJ Category:

Description

Product Overview / 商品概要

Lyumjev Injection Cartridge 100 units/mL (300 units per 3mL cartridge) (ルムジェブ注カート)
Generic: Insulin Lispro (Genetical Recombination) / インスリン リスプロ(遺伝子組換え)
Therapeutic Category: Antidiabetic Agent / 抗糖尿病剤
Manufactured by: Eli Lilly Japan K.K. / 日本イーライリリー株式会社

Composition & Specification / 組成・規格

Active Ingredient: Insulin Lispro (Genetical Recombination) 300 units per cartridge / 1カートリッジ中 インスリン リスプロ(遺伝子組換え)300単位
Additives: Concentrated glycerin 36.3mg, Magnesium chloride 3.06mg, m-Cresol 9.45mg, Sodium citrate hydrate 13.23mg, Treprostinil sodium 3.18μg, Zinc oxide (as zinc content) 118μg, pH adjusting agent q.s. / 濃グリセリン 36.3mg、塩化マグネシウム 3.06mg、m-クレゾール 9.45mg、クエン酸ナトリウム水和物 13.23mg、トレプロスチニルナトリウム 3.18μg、酸化亜鉛(亜鉛含量として) 118μg、pH調節剤 適量
Appearance: Clear, colorless solution (injection); pH 7.0–7.8; osmolality ratio (relative to physiological saline) approximately 0.8
外観: 無色澄明の液(注射剤)、pH 7.0~7.8、浸透圧比(生理食塩液に対する比)約0.8

Indications / 効能効果

EN: Diabetes mellitus requiring insulin therapy
JA: インスリン療法が適応となる糖尿病

Dosage and Administration / 用法用量

EN: Typically, adults receive 2 to 20 units subcutaneously at the start of each meal; administration after meal initiation is also possible if necessary. The dosing frequency may be increased or combined with a long-acting insulin preparation as needed. The dose should be adjusted according to the patient’s symptoms and test findings; the usual maintenance dose, including any long-acting insulin, is 4 to 100 units per day.
JA: 通常、成人では1回2~20単位を毎食事開始時に皮下注射するが、必要な場合は食事開始後の投与とすることもできる。ときに投与回数を増やしたり、持続型インスリン製剤と併用したりすることがある。投与量は、患者の症状及び検査所見に応じて適宜増減するが、持続型インスリン製剤の投与量を含めた維持量としては通常1日4~100単位である。

Contraindications / 禁忌

EN: 2.1 Patients presenting with hypoglycemic symptoms; 2.2 Patients with a history of hypersensitivity to insulin lispro or any component of this product
JA: 2.1 低血糖症状を呈している患者、2.2 インスリンリスプロ又は本剤の成分に対して過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 30200AMX00441
Sales Started: June 2020 / 2020年6月
Classification Code: 872492
Storage: Store at 2–8°C / 2~8℃で保存
Shelf Life: 36 months / 36ヵ月

Packaging / 包装

Main Package (for sale): 3mL x 2 cartridges / 3mL×2カートリッジ
Other Available Packages (by special order): 3mL x 2 cartridges

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Insulin Lispro (Genetical Recombination) Injection 100 units/mL (Lyumjev® / ルムジェブ注カート)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Insulin Lispro (Genetical Recombination) Injection 100 units

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.